Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors
A Chennamadhavuni, L Abushahin, N Jin… - Frontiers in …, 2022 - frontiersin.org
Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
JR Brahmer, H Abu-Sbeih, PA Ascierto… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …
cancers. While these immunotherapies have improved patient outcomes in many clinical …
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
RJ Sullivan, JS Weber - Nature reviews Drug discovery, 2022 - nature.com
The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
[HTML][HTML] Immune mechanisms of toxicity from checkpoint inhibitors
SJ Wang, SK Dougan, M Dougan - Trends in cancer, 2023 - cell.com
Immunotherapy has changed the treatment landscape for cancer over the past decade.
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …
Understanding and treating the inflammatory adverse events of cancer immunotherapy
M Dougan, AM Luoma, SK Dougan… - Cell, 2021 - cell.com
During the past decade, immunotherapies have made a major impact on the treatment of
diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and …
diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and …
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
M Pinter, B Scheiner, M Peck-Radosavljevic - Gut, 2021 - gut.bmj.com
Following the success of immune checkpoint blockers (ICBs) in different cancer types, a
large number of studies are currently investigating ICBs in patients with hepatocellular …
large number of studies are currently investigating ICBs in patients with hepatocellular …
AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review
M Dougan, Y Wang, A Rubio-Tapia, JK Lim - Gastroenterology, 2021 - Elsevier
Background & Aims Immune checkpoint inhibitors (ICIs) have transformed the treatment
landscape for oncology, leading to durable remissions in a subset of patients, but also a …
landscape for oncology, leading to durable remissions in a subset of patients, but also a …
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …
advanced cancers. Designed to enhance the antitumour immune response, they can also …
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …